Brussels, 15/11/2012 (Agence Europe) - In view of the upcoming discussions at the European Parliament on new legislation on clinical trials, the European Federation of Pharmaceutical Industries and Associations (EFPIA) is calling on all stakeholders to collaborate to improve the transparency recommended by the European Commission. The transparency of data and the sharing of results is one of the key elements of the Commission proposals to reinvigorate clinical research (see EUROPE 10657). “Medicines should benefit patients. We support measures that enhance the way they are used and enable the industry to continue to innovate. These measures include improved transparency”, stated the EFPIA director general, Richard Bergström. EFPIA nonetheless calls for a “responsible” transparency that respects personal privacy and commercial confidentiality. On 17 July, the Commission adopted a proposal for a regulation to reinvigorate clinical research in Europe - which is of the utmost importance for development of new medicines, and improving medicines that are already authorised and existing treatments. The proposed measures will enable procedures to be accelerated and simplified while preserving rigorous standards - be it with regard to patient safety or the reliability of data. (IL/transl.fl)